Greenwich LifeSciences's quarterly market cap
declined
from Sep. 2024 ($188.89 Mil) to Dec. 2024 ($147.71 Mil) and
declined
from Dec. 2024 ($147.71 Mil) to Mar. 2025 ($125.86 Mil).
Greenwich LifeSciences's annual market cap
declined
from Dec. 2022 ($195.29 Mil) to Dec. 2023 ($135.16 Mil) but then
increased
from Dec. 2023 ($135.16 Mil) to Dec. 2024 ($147.71 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Greenwich LifeSciences's Enterprise Value for Today is $117.57 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Greenwich LifeSciences's Market Cap
For the Biotechnology subindustry, Greenwich LifeSciences's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Greenwich LifeSciences's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Greenwich LifeSciences's Market Cap distribution charts can be found below:
* The bar in red indicates where Greenwich LifeSciences's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Greenwich LifeSciences's Market Cap for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Greenwich LifeSciences (NAS:GLSI) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Greenwich LifeSciences Market Cap Related Terms
Thank you for viewing the detailed overview of Greenwich LifeSciences's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
GLSI has been successfully added to your 